PLK4 and cancer: For example, CFI-400945, a potent Polo-like kinase 4 (PLK4) inhibitor, and RV-521, a viral fusion inhibitor, advanced into Phase II clinical trials for the treatment of human cancers and RSV infection, respectively (Figure 1) [4,5].